Sucampo Pharmaceuticals, Inc. – Non-Competition Agreement (December 29th, 2010)
This NON-COMPETITION AGREEMENT (this "Agreement") is dated as of December 23, 2010, by and among Dr. Ryuji Ueno, as trustee of the Ryuji Ueno Revocable Trust under Trust Agreement dated December 20, 2002 (the "Ueno Trust"), and Dr. Sachiko Kuno as trustee of the Sachiko Kuno Revocable Trust under Trust Agreement dated December 20, 2002 (the "Kuno Trust") (each a "Shareholder" and collectively, the "Shareholders"), Dr. Ryuji Ueno, an individual ("Ueno"), and Dr. Sachiko Kuno, an individual ("Kuno" and collectively with Ueno, the "Principals" and together with the Shareholders, each a "Seller" and collectively, the "Sellers"), and Ambrent Investments S.a r.l., a company organized under the laws of Luxembourg (the "Purchaser"), and Sucampo Pharmaceuticals, Inc., a Delaware corporation (the "Parent"). Any capitalized terms used but not defined in this Agreement have the respective meanings set forth in the SPA (as defined below).
Sucampo Pharmaceuticals, Inc. – Employment Agreement (October 5th, 2009)
THIS EMPLOYMENT AGREEMENT (the "Agreement"), dated as of September 30, 2009, is hereby entered into in the State of Maryland by and between SUCAMPO PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and JAMES J. EGAN ("Executive").
Idenix Pharmaceuticals, Inc. – Re: Modification of Employment Agreement (The Employment Agreement) Dated May 8, 2003 by and Between James Egan and Idenix Pharmaceuticals, Inc. (The Company) (January 9th, 2006)
This letter confirms our mutual agreement to modify your Employment Agreement with respect to the benefits payable to you in connection with the termination of your employment with Idenix (the Modification). This Modification and the termination of your employment with Idenix will have effect as of the date hereof (the Termination Date).
Idenix Pharmaceuticals, Inc. – Contract (January 27th, 2004)
EXHIBIT 10.29 April 24, 2000 Jean-Pierre Sommadossi, Ph.D. Chief Executive Officer and Chairman of the Board of Directors Novirio Pharmaceuticals Limited c/o Walker Secretaries Box 265 Grand Cayman, Cayman Islands Dear Jean-Pierre: This Letter Agreement entered into as of the date hereof is intended to set forth the terms of appointment, representation, and compensation of James J. Egan of 2-6 Park Road, Grafton, Auckland, New Zealand ("Egan") for his activities on behalf of Novirio Pharmaceuticals Limited, a company organized and existing under the laws of the Cayman Islands (together with its subsidiaries, successors and assigns, "Novirio"): 1. Definitions. For purposes hereof, the following terms shall have the meanings set forth below: "Confidentiality Agreement" means the Confidentiality and Non-disclosure Agreement dated as of May 10, 2000 between Novirio and Egan. "Novirio HBV Drug Candidate" means any of the nucleoside compounds commonly referred to by Noviri
Idenix Pharmaceuticals, Inc. – Contract (December 15th, 2003)
EXHIBIT 10.7 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement") is made this 8th day of May, 2003 between Idenix Pharmaceuticals, Inc., a corporation domesticated under the laws of the State of Delaware (together with its successors and assigns, the "Company") and James Egan (the "Employee"). WHEREAS, the Employee is currently employed as the Senior Vice President, Business and Corporate Development of the Company; WHEREAS, the Employee is a shareholder of the Company and a holder of options to purchase shares of the Company's capital stock; WHEREAS, Novartis Pharma AG, a corporation organized under the laws of Switzerland, has entered into a Stock Purchase Agreement with the Company, dated as of March 21, 2003 (the "Purchase Agreement") pursuant to which Novartis Pharma AG will acquire a majority of the fully diluted outstanding shares of the Company from the shareh